HCV Treatment
Predictors of Sustained Treatment Response in HIV-HCV Coinfected Patients Receiving Routine Care
- Details
- Category: HCV Treatment
- Published on Tuesday, 16 June 2009 13:41
- Written by Liz Highleyman
As reported at the recent Digestive Disease Week annual meeting (DDW 2009) in Chicago, Lisa Backus and colleagues evaluated the predictors of sustained virological response (SVR) for HIV-HCV coinfected patients receiving pegylated interferon plus ribavirin in routine care at Veterans Affairs (VA) medical facilities.
DDW 2009: Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 05 June 2009 13:41
- Written by Liz Highleyman
Serum levels of vitamin B12 may be among the factors that can help predict whether patients with chronic hepatitis C virus (HCV) infection will respond to interferon-based treatment, according to a study by researchers from the Karolinska Institute in Stockholm presented this week at the annual Digestive Disease Week (DDW 2009) meeting in Chicago.
Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
- Details
- Category: HCV Treatment
- Published on Monday, 18 May 2009 18:19
- Written by Liz Highleyman
Active injection drug users (IDUs) and those receiving opiate substitution can be successfully treated for chronic hepatitis C virus (HCV) infection, according to a French study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
EASL 2009: Antiviral Agents with Activity against Both HIV and Hepatitis C Virus
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 June 2009 13:47
- Written by Liz Highleyman
Standard therapy for chronic hepatitis C virus (HCV) infection consists of pegylated interferon plus ribavirin, but several novel agents under study directly target various steps of the HCV lifecycle, an approach known as "STAT-C." Some of these investigational agents work similarly to certain antiretroviral drugs for HIV, suggesting it may be possible to develop drugs that have activity against both HIV-HCV, a potential benefit for HIV-HCV coinfected patients.
Researchers Present Data on Investigational Cyclophilin Inhibitors Debio 025 and SCY-635
- Details
- Category: HCV Treatment
- Published on Friday, 15 May 2009 13:47
- Written by Liz Highleyman
At the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, researchers presented promising data from studies of a new class of agents for HCV therapy, cyclophilin inhibitors.
More Articles...
- New England Journal of Medicine Publishes Promising Data from PROVE 1 and PROVE 2 Studies of HCV Protease Inhibitor Telaprevir
- Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
- Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients
- A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
Web Design and Development by